Literature DB >> 17412915

Recombinant ST2 boosts hepatic Th2 response in vivo.

Aldo Amatucci1, Tatiana Novobrantseva, Kevin Gilbride, Margot Brickelmaier, Paula Hochman, Alexander Ibraghimov.   

Abstract

Excessive scarring or fibrosis is a common feature of a wide spectrum of diseases characterized by an exaggerated Th2 response. The TLR/IL-1 receptor (IL-1R)-related protein ST2 is expressed in a membrane-bound form selectively by Th2 cells and was shown to be indispensable for some in vivo Th2 responses. ST2 was also found to block TLR signaling. We addressed the impact of the ST2 pathway on fibrogenesis using a mouse model of hepatic injury and fibrosis induced by carbon tetrachloride (CCl(4)). We showed that cytokine production by intrahepatic lymphocytes from CCl(4)-injured liver is abrogated in the absence of TLR-4. Interfering with the ST2 pathway using an ST2-Fc fusion protein accelerated and enhanced hepatic fibrosis, paralleled by the increasing ex vivo secretion of Th2 cytokines IL-4, -5, -10, and -13 by intrahepatic lymphocytes of ST2-Fc-treated, CCl(4)-gavaged mice. Absence of IL-4/13 signaling in IL-4Ralpha-deficient mice obliterated this ST2-Fc effect on fibrogenesis. Moreover, depletion of CD4(+) T cells abrogated ST2-Fc-enhanced Th2 cytokines and accelerated fibrosis. Thus, ST2-Fc caused overproduction of Th2 cytokines by intrahepatic CD4(+) T cells, possibly by modifying TLR-4 signaling in injured liver. This ST2-Fc-driven Th2 response exacerbated CCl(4)-induced hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412915     DOI: 10.1189/jlb.1006625

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  10 in total

1.  IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation.

Authors:  Matthew R Silver; Alexander Margulis; Nancy Wood; Samuel J Goldman; Marion Kasaian; Divya Chaudhary
Journal:  Inflamm Res       Date:  2009-09-18       Impact factor: 4.575

2.  The role of ST2 and ST2 genetic variants in schistosomiasis.

Authors:  Xin Long; Michelle Daya; Jianping Zhao; Nicholas Rafaels; Huifang Liang; Joseph Potee; Monica Campbell; Bixiang Zhang; Maria Ilma Araujo; Ricardo R Oliveira; Rasika A Mathias; Li Gao; Ingo Ruczinski; Steve N Georas; Donata Vercelli; Terri H Beaty; Kathleen C Barnes; Xiaoping Chen; Qian Chen
Journal:  J Allergy Clin Immunol       Date:  2017-02-09       Impact factor: 10.793

3.  A panel of four cytokines predicts the prognosis of patients with malignant gliomas.

Authors:  Yi Lin; Guozhen Zhang; Jing Zhang; Guangzu Gao; Min Li; Yong Chen; Jiangfei Wang; Guilin Li; Sonya-Wei Song; Xiaoguang Qiu; Yunjie Wang; Tao Jiang
Journal:  J Neurooncol       Date:  2013-06-08       Impact factor: 4.130

Review 4.  The IL-33/ST2 pathway: therapeutic target and novel biomarker.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

Review 5.  Inflammasome activation and function in liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

6.  Elevated levels of soluble ST2 protein in dengue virus infected patients.

Authors:  Aniuska Becerra; Rajas V Warke; Norma de Bosch; Alan L Rothman; Irene Bosch
Journal:  Cytokine       Date:  2008-01-28       Impact factor: 3.861

7.  New insights into the mechanisms of innate immune receptor signalling in fibrosis.

Authors:  Robert Lafyatis; Alessandra Farina
Journal:  Open Rheumatol J       Date:  2012-06-15

8.  Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis.

Authors:  Loris R Lopetuso; Franco Scaldaferri; Theresa T Pizarro
Journal:  Fibrogenesis Tissue Repair       Date:  2012-10-14

9.  Interleukin-33 overexpression is associated with liver fibrosis in mice and humans.

Authors:  Pierrick Marvie; Mariette Lisbonne; Annie L'helgoualc'h; Michel Rauch; Bruno Turlin; Laurence Preisser; Katia Bourd-Boittin; Nathalie Théret; Hugues Gascan; Claire Piquet-Pellorce; Michel Samson
Journal:  J Cell Mol Med       Date:  2009-06-05       Impact factor: 5.310

10.  Can Serum ST2 Levels Be Used as a Marker of Fibrosis in Chronic Hepatitis B Infection?

Authors:  Erkin Oztas; Ufuk Baris Kuzu; Neslihan Inci Zengin; Ismail Hakki Kalkan; Fatih Saygili; Hakan Yildiz; Huseyin Tugrul Celik; Meral Akdogan; Mesut Yalin Kilic; Aydin Seref Koksal; Bulent Odemis; Nuretdin Suna; Ertugrul Kayacetin
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.